MAPK Pathway-Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial.

Saved in:
Bibliographic Details
Title: MAPK Pathway-Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial.
Authors: Cappuzzo F; Department of Medical Oncology 2, IRCCS 'Regina Elena' National Cancer Institute, Rome, Italy., Ricciuti B; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Delmonte A; Medical Oncology Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Bonanno L; Medical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy., Wang X; Vela Diagnostics Germany GmbH, Hamburg, Germany., Lye WK; Vela Research Singapore Pte Ltd., Singapore, Singapore., Görtz A; Vela Diagnostics Germany GmbH, Hamburg, Germany., Andrikou K; Medical Oncology Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Dal Maso A; Medical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy., Minuti G; Department of Medical Oncology 2, IRCCS 'Regina Elena' National Cancer Institute, Rome, Italy., Papi M; Department of Medical Oncology, Per gli Infermi Hospital, Rimini, Italy., Alessi JV; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Di Federico A; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Rodig S; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Awad MM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Metro G; Medical Oncology Department, S. Maria Della Misericordia Hospital, Perugia, Italy., Attili I; Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy., Vitiello F; Department of Pneumology and Oncology, AORN Ospedali dei Colli-Monaldi Naples, Naples, Italy., Pilotto S; Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy., Gori S; Medical Oncology Department, IRCCS-Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy., Rossi G; Oncology Department, Ravenna Hospital, Ravenna, Italy., Buglioni S; Department of Medical Oncology 2, IRCCS 'Regina Elena' National Cancer Institute, Rome, Italy., Giannarelli D; Department of Epidemiology and Biostatistics, GSTeP, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy., Landi L; Department of Medical Oncology 2, IRCCS 'Regina Elena' National Cancer Institute, Rome, Italy.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Mar 17; Vol. 31 (6), pp. 1027-1036.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-24-2077